Intratumoral Gene Expression of Dihydrofolate Reductase and Folylpoly-c-glutamate Synthetase Affects the Sensitivity to 5-fluorouracil in Non-small Cell Lung Cancer

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2022 Feb 24

PMID 35201464

Authors

Kayo Sakon

Masato Sasaki

Kaede Tanaka

Tae Mizunaga

Keita Yano

Yuuko Kawamura

Akitoshi Okada

Takeshi Ikeda

Sawaka Tanabe

Atsushi Takamori

Narihisa Yamada

Kouichi Morioka

Takaaki Koshiji

Affiliations

Soon will be listed here.

Abstract

Background: Various factors related to the sensitivity of non-small cell lung carcinoma (NSCLC) to 5-fluorouracil (5-FU) have been reported, and some of them have been clinically applied. In this single-institutional prospective analysis, the mRNA expression level of five folic acid-associated enzymes was evaluated in surgical specimens of NSCLC. We investigated the correlation between the antitumor effect of 5-FU in NSCLC using an anticancer drug sensitivity test and the gene expression levels of five enzymes.

Materials And Methods: Forty patients who underwent surgery for NSCLC were enrolled, and the antitumor effect was measured using an in vitro anticancer drug sensitivity test (histoculture drug response assay) using freshly resected specimens. In the same sample, the mRNA expression levels of five enzymes involved in the sensitivity to 5-FU were measured in the tumor using real-time PCR. The expression levels and the result of the sensitivity test were compared.

Results: No correlation was found between dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), or DPD/OPRT expression and the antitumor effects of 5-FU. On the other hand, a correlation was found between thymidylate synthase (TS), folylpoly-c-glutamate synthetase (FPGS), and dihydrofolate reductase (DHFR) expression and 5-FU sensitivity.

Conclusion: Expression of FPGS and DHFR may be useful for predicting the efficacy of 5-FU-based chemotherapy for NSCLC.

References

Konishi Y, Kanamaru R, Ishioka C, Ishikawa A, Shibata H, WAKUI A . The changes in the levels of dihydrofolate reductase mRNA and its gene dosage in 5-fluorouracil-resistant L1210 cells. Tohoku J Exp Med. 1990; 161(1):33-42. DOI: 10.1620/tjem.161.33. View

Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K . Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res. 2000; 91(1):105-12. PMC: 5926227. DOI: 10.1111/j.1349-7006.2000.tb00866.x. View

Fukui Y, Oka T, Nagayama S, Danenberg P, Danenberg K, Fukushima M . Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 2008; 22(6):709-16. View

Kubota T, Sasano N, Abe O, NAKAO I, Kawamura E, Saito T . Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res. 1995; 1(12):1537-43. View

Inoue K, Takao M, Watanabe F, Tarukawa T, Shimamoto A, Kaneda M . Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Lung Cancer. 2005; 49(1):47-54. DOI: 10.1016/j.lungcan.2004.12.007. View

Arkenau H, Bermann A, Rettig K, Strohmeyer G, Porschen R . 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol. 2003; 14(3):395-9. DOI: 10.1093/annonc/mdg100. View

Sohn K, Smirnakis F, Moskovitz D, Novakovic P, Yates Z, Lucock M . Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. Gut. 2004; 53(12):1825-31. PMC: 1774322. DOI: 10.1136/gut.2004.042713. View

Kimura M, Imamura F, Inoue T, Nishino K, Uchida J, Kumagai T . Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer. Mol Clin Oncol. 2017; 7(1):15-23. PMC: 5492704. DOI: 10.3892/mco.2017.1262. View

Lord R, Salonga D, Danenberg K, Peters J, DeMeester T, Park J . Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000; 4(2):135-42. DOI: 10.1016/s1091-255x(00)80049-9. View

10.

Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350(17):1713-21. DOI: 10.1056/NEJMoa032792. View

11.

Eguchi K, Oyama T, Tajima A, Abiko T, Sawafuji M, Horio H . Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan. Lung Cancer. 2014; 87(1):53-8. DOI: 10.1016/j.lungcan.2014.10.013. View

12.

Cho R, Cole P, Sohn K, Gaisano G, Croxford R, Kamen B . Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells. Mol Cancer Ther. 2007; 6(11):2909-20. DOI: 10.1158/1535-7163.MCT-07-0449. View

13.

Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z . Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003; 89(8):1486-92. PMC: 2394351. DOI: 10.1038/sj.bjc.6601335. View

14.

Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H . Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer. 2006; 95(5):607-15. PMC: 2360692. DOI: 10.1038/sj.bjc.6603297. View

15.

Furukawa T, Kubota T, Hoffman R . Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995; 1(3):305-11. View

16.

Danenberg P, Gustavsson B, Johnston P, Lindberg P, Moser R, Odin E . Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action. Crit Rev Oncol Hematol. 2016; 106:118-31. DOI: 10.1016/j.critrevonc.2016.08.001. View

17.

Takechi T, Okabe H, Ikeda K, Fujioka A, Nakagawa F, Ohshimo H . Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Rep. 2005; 14(1):33-9. View

18.

Grimminger P, Schneider P, Metzger R, Vallbohmer D, Holscher A, Danenberg P . Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer. 2010; 11(5):328-34. DOI: 10.3816/CLC.2010.n.041. View

19.

Botelho N, Schneiders F, Lord S, Freeman A, Tyagi S, Nancarrow D . Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues. Cancer Biol Ther. 2010; 10(2):172-9. DOI: 10.4161/cbt.10.2.12166. View

20.

Vescio R, Redfern C, Nelson T, Ugoretz S, Stern P, Hoffman R . In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A. 1987; 84(14):5029-33. PMC: 305240. DOI: 10.1073/pnas.84.14.5029. View